Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo.

mBio - 12 Jun 2024

Kober Daniel L, Caballero Van Dyke Marley C, Eitson Jennifer L, Boys Ian N, McDougal Matthew B, Rosenbaum Daniel M, Schoggins John W

Abstract excerpt

The rapid evolution of SARS-CoV-2 variants highlights the need for new therapies to prevent disease spread. SARS-CoV-2, like SARS-CoV-1, uses the human cell surface protein angiotensin-converting enzyme 2 (ACE2) as its native receptor. Here, we design and characterize a mutant ACE2 that enables rapid affinity purification of a dimeric protein by altering the active site to prevent autoproteolytic digestion of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ACE2 gene

Share to HEK293 Cells

Share to Mutation

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 38771062
DOI: 10.1128/mbio.00768-24
PMCID: PMC11237572

Genes

ACE2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo.PMID 38771062Read ↗

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivoSemantic proximity Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

ACE2-based decoy receptors for SARS coronavirus 2.Semantic proximity Read ↗

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesSemantic proximity Read ↗

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.Semantic proximity Read ↗

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2Semantic proximity Read ↗

Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infectionSemantic proximity Read ↗

A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitroSemantic proximity Read ↗

Intranasal gene therapy to prevent infection by SARS-CoV-2 variantsSemantic proximity Read ↗

A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infectionSemantic proximity Read ↗

Novel ACE2 nanoparticles universally block SARS-CoV-2 variants in the human respiratory tractSemantic proximity Read ↗

Intranasal gene therapy to prevent infection by SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.